Quality Issues Found at Brazil Drug Manufacturing Facility
FDA issued a warning letter to Lima & Pergher Industria e Comercio S/A for CGMP violations.
On August 25, 2016, FDA issued a warning letter to Lima & Pergher Industria e Comercio S/A following an inspection of the company’s facility in Uberlandia, Brazil, performed from February 29–March 3, 2016. The company was cited for current good manufacturing practice (CGMP) violations specific to ensuring quality in their products. FDA placed the company on Import Alert 66-40 on July 15, 2016.
FDA inspectors found that the company had not established adequate written procedures for its quality control unit, including the review and approval of production and control records and the handling and review of out-of-specification investigations. The company also failed to perform microbiological testing on each lot of finished product.
Components, drug product containers, or closures were released that did not meet appropriate specifications for identity, strength, quality, and purity. Inspectors also found that expiration dates on products were not supported by stability data.
FDA stated in the letter that the company’s response to the FDA 483 was inadequate. “Although you committed to establish written procedures for quality unit responsibilities and stability studies, your response lacked details. You did not include a retrospective review of CGMP deficiencies on the quality of your products already in United States distribution,” the agency stated. FDA recommends the company hire a consultant to assist in meeting CGMP requirements.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
